CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2013-12-31 | Ahn Mark J President & CEO | Other acquisition | +5,656 | $1.88 | $11K | 113,764 |
| 2013-12-31 | SCHWARTZ MARK W. EVP & Chief Operating Officer | Other acquisition | +5,656 | $1.88 | $11K | 509,665 |
| 2013-12-31 | Dunlap Ryan Principal Accounting Officer | Other acquisition | +2,728 | $1.88 | $5K | 5,343 |
| 2013-11-26 | Ahn Mark J President and CEO | Grant or award · Stock Option (right to buy) | +600,000 | 600,000 |
Page 17 of 17 · 324 trades